All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Amlodipine,Atorvastatin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Caduet
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Viatris
Deal Size: $12,000.0 million Upfront Cash: Undisclosed
Deal Type: Merger November 16, 2020
Details:
Merger of Pfizer's Upjohn with Mylan brings trusted, iconic brands, such as Lipitor, Celebrex and Viagra, and proven commercialization capabilities, including leadership positions in China and other emerging markets.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IBUTILIDE FUMARATE
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Premier
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 19, 2020
Details:
Premier’s ProvideGx program identifies safe, high-quality supply sources for drugs that are or may be at risk of being added to the national drug shortage list.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Fondaparinux
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Arixtra
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Mylan Inc
Deal Size: $757.2 million Upfront Cash: $310.4 million
Deal Type: Acquisition September 08, 2020
Details:
Under the terms of the agreement, Mylan Ireland Limited will acquire the commercialisation rights and related intellectual property relating to Aspen’s Thrombosis Business in Europe which includes Arixtra, Fraxiparine, Mono-Embolex and Orgaran.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Icosapent Ethyl
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vascepa
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Details:
Amarin Corporation plc announced that scientific findings that add to the growing body of knowledge on VASCEPA® (icosapent ethyl) will be presented during the National Lipid Association (NLA) Scientific Sessions 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Rosuvastatin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Crestor
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Grunenthal
Deal Size: $350.0 million Upfront Cash: $320.0 million
Deal Type: Divestment December 01, 2020
Details:
Crestor is a statin approved for the treatment of dyslipidaemia and hypercholesterolaemia. The deal will give Gruenenthal rights to sell Crestor and associated medicines in more than 30 countries in Europe, except the UK and Spain.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Atenolol,Chlorthalidone
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2020
Details:
Atenolol and Chlorthalidone Tablets are indicated for the treatment of hypertension, to lower blood pressure. The product will be commercialized from Unichem’s Ghaziabad Plant.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Heparin Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Fresenius Kabi AG
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 18, 2020
Details:
Premier with Fresenius Kabi aims at supplying pre-filled, single-use IV bags of heparin sodium injection, USP to healthcare providers, helping to stabilize the long-term supply of a medication that is necessary when performing a number of hospital inpatient procedures.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
